Beyond Semaglutide: Amycretin, Ecnoglutide, Orforglipron and Survodutide Side by Side

The four compounds usually lumped together as "next-generation GLP-1s" are not four takes on the same idea — each stands for a distinct strategic wager: bolt on amylin (amycretin), refine the GLP-1 backbone itself (ecnoglutide), drop peptides altogether in favour of an oral small molecule (orforglipron), or bolt on glucagon (survodutide). When you choose a reference standard, the receptor target and the class of molecule count for much more than the headline percentage linked to each name.

Amycretin: a single chain for two hormone systems

Conceptually, amycretin is the most intriguing of the group because it is a single molecule. Instead of formulating a GLP-1 analog together with a separate amylin analog, its sequence is designed so that one chain activates both the GLP-1 receptor and the amylin/calcitonin receptor complexes. Early-phase results shown during 2025 described large mean reductions in body weight at roughly 36 weeks in the highest-exposure study arms, subject to the familiar early-phase reservations: few participants, short follow-up, and unresolved tolerability questions at the upper end.

For research, this places amycretin mechanistically next to fixed-ratio combinations rather than making them obsolete. If your study asks whether amylin and GLP-1 signalling add up at receptor level, a combination such as semaglutide + cagrilintide allows the ratio to be varied in principle, whereas a single-molecule agent fixes it. Research-grade amycretin comes as a lyophilised vial for exactly this kind of comparison; the amylin pharmacology behind it is explained in the CagriSema and amylin analogs article.

Ecnoglutide: a refined backbone, not a new target

Ecnoglutide (XW003) is a long-acting GLP-1 analog, developed mainly in China, that is reported to be tuned toward cAMP-biased signalling at the GLP-1 receptor. Its selling point is efficiency, not novelty: the receptor is the same, but the signalling profile is meant to favour the pathway linked to metabolic effects over the pathways linked to receptor internalisation. Phase-3 studies in Chinese populations reported relevant effects on weight and glycaemia and have underpinned regulatory submissions in the region.

In a research programme, ecnoglutide works best as a comparator that isolates a single variable. Measured against semaglutide in the same receptor assay, any differences can be traced to backbone and acylation chemistry rather than to additional receptor arms. Ecnoglutide research vials are supplied in 5 mg and 10 mg sizes with this in mind.

Orforglipron: the non-peptide in the group

Orforglipron is the odd one out and calls for a different way of thinking. It is an orally bioavailable small-molecule GLP-1 receptor agonist with no peptide structure, so none of the usual peptide handling rules apply — no freeze-dried cake, no reconstitution maths, no counter-ion correction, no worries about the cold chain. Studies have looked at once-daily oral administration without the fasting and water-volume rules that oral semaglutide tablets impose, since its absorption does not rely on a permeation enhancer.

That is precisely the purpose of the molecule. If GLP-1 receptor pharmacology can be delivered orally by a small molecule that is easy to manufacture, the economics of supplying the class shift. At the bench, orforglipron research capsules act like any standard small-molecule reference compound; confirming identity is a question of mass and chromatography, not of peptide sequence. The contrast with oral semaglutide research tablets is instructive: there it is the formulation, not the molecule, that achieves absorption — the tablet needs a permeation enhancer and strict fasting conditions to get a peptide across the stomach lining at all.

Survodutide: betting on glucagon

Survodutide (BI 456906) is an acylated peptide that acts as a dual agonist at GLP-1 and glucagon receptors. Its most characteristic published finding concerns the liver: phase-2 research in metabolic dysfunction-associated steatohepatitis found that a large share of participants reached histological improvement endpoints — a different kind of outcome from a weight percentage. Phase-2 studies in obesity reported average reductions in the high teens at about 46 weeks, and a phase-3 programme came next.

Activity at the glucagon receptor is what survodutide has in common with mazdutide and the triple agonist retatrutide, so the three are typically investigated as a group. The design balance — liver fat mobilisation and energy expenditure on one side, hepatic glucose output and heart rate on the other — is identical for each. Survodutide vials come in 5–20 mg sizes, and a direct comparison with the catalogue’s other dual agonist is available in survodutide vs mazdutide.

Picking the right reference standard

Start from the receptor question and work back. For additivity of amylin and incretin signalling, compare amycretin with fixed-ratio amylin combinations. For GLP-1 receptor signalling bias, set ecnoglutide against semaglutide. For oral bioavailability without peptide chemistry, orforglipron is the only candidate of the four that fits. For the contribution of the glucagon receptor, survodutide is the cleanest dual-agonist tool, as it lacks a GIP arm that could muddy the result.

Every one of the four is still investigational. None has US approval, none of the clinical findings applies to research-grade lyophilised material, and all are supplied for laboratory use only. Class-level context sits in the GLP-1 and incretin collection, and the vocabulary is defined at dual agonist.